Antisense Oligonucleotides for the Treatment of Neurological Diseases

Jun 7, 2021 9:10am ‐ Jun 7, 2021 9:35am

Identification: ek48-48-esym-session-Kordasiewicz-Holly


Therapeutic Strategies for the Treatment of Neurodegenerative Disease Based on Human Genetics

Jun 7, 2021 9:35am ‐ Jun 7, 2021 10:00am

Identification: ek48-48-esym-session-Lewcock-Joseph


Enhancing Microglia Function with ATV:TREM2

Jun 7, 2021 10:00am ‐ Jun 7, 2021 10:25am

Identification: ek48-48-esym-session-Monroe-Kate


Coffee Break

Jun 7, 2021 10:25am ‐ Jun 7, 2021 10:50am

Identification: _esym-session-break-01


Neuroimmunological Target Considerations - To Be or Not To Be in the Brain

Jun 7, 2021 10:50am ‐ Jun 7, 2021 11:15am

Identification: ek48-48-esym-session-Luthman-Johan


Short Talk: TREM2-Independent Neuroprotection Mediated by Monocyte-Derived Macrophages in a Mouse Model of Alzheimer’s Disease

Jun 7, 2021 11:15am ‐ Jun 7, 2021 11:30am

Identification: ek48-48-esym-session-Dvir Szternfeld-Raz


Short Talk: Myokine Irisin Is a Critical Regulator of Cognitive Function

Jun 7, 2021 11:30am ‐ Jun 7, 2021 11:45am

Identification: ek48-48-esym-session-Wrann-Christiane


Short Talk: Highly Conserved Glial Pathology and Human-Specific Neuronal Pathology Promote Neurodegeneration in FTLD-GRN

Jun 7, 2021 11:45am ‐ Jun 7, 2021 12:00pm

Identification: ek48-48-esym-session-Marsan-Elise


The Evolving Challenges of Gene Targeted Therapeutics for SMA

Jun 7, 2021 12:00pm ‐ Jun 7, 2021 12:25pm

Identification: ek48-esym-session-Sumner-Charlotte


From Therapeutic Targets to Clinic

Jun 7, 2021 12:00pm ‐ Jun 7, 2021 1:30pm

Identification: _esym-session-targets